Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580615 | 1.00 | ADRB2 (0.36) | ADRB2AOC3LMNATSHRKDM4E | |
| SCHEMBL3024798 | 0.88 | ADRB2 (0.34) | ADRB2AOC3 | |
| SCHEMBL2831936 | 0.77 | ADRB2 (0.41) | ADRB2LMNATSHRKDM4EMEN1 | |
| SCHEMBL925596 | 0.77 | ADRB2 (0.41) | ADRB2LMNATSHRKDM4EMEN1 | |
| SCHEMBL2012341 | 0.76 | NFKB1 (0.41) | ADRB2AOC3LMNATSHRKDM4E | |
| SCHEMBL2569901 | 0.76 | ADRB2 (0.38) | ADRB2AOC3 | |
| SCHEMBL1205580 | 0.76 | NFKB1 (0.41) | ADRB2AOC3LMNATSHRKDM4E | |
| SCHEMBL828863 | 0.76 | ADRB2 (0.38) | ADRB2AOC3 | |
| SCHEMBL17651818 | 0.76 | ADRB2 (0.38) | ADRB2AOC3TSHR | |
| SCHEMBL1204929 | 0.76 | NFKB1 (0.41) | ADRB2AOC3LMNATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | ADRA2C, ADRB2, ADRB3 | ADRB2 2/4885AOC3 533/4885LMNA 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.